During Q3 2018 the big money sentiment decreased to 0.74. That’s change of 0.11, from 2018Q2’s 0.85. 29 investors sold all, 170 reduced holdings as DaVita Inc. ratio is negative. 94 rose holdings while 53 funds took holdings. Funds hold 134.94 million shares thus 5.12% less from 2018Q2’s 142.23 million shares.
Cipher Ltd Partnership owns 20,062 shs. Aviva Public Lc holds 0.02% or 63,510 shs. Aqr Management Lc holds 0% or 39,871 shs in its capital. Quinn Opportunity Prns Lc reported 6,000 shs stake. Duncker Streett And Company holds 630 shs. Oppenheimer & Incorporated holds 0.03% of its capital in DaVita Inc. (NYSE:DVA) for 15,863 shs. Northwestern Mutual Wealth Communications stated it has 0% in DaVita Inc. (NYSE:DVA). Bridgewater Associate L P reported 190,154 shs. British Columbia Investment Management Corp has invested 0.02% of its capital in DaVita Inc. (NYSE:DVA). Walleye Trading Lc holds 151,784 shs or 0.06% of its capital. Hightower Advsrs Limited Liability, a Illinois-based fund reported 18,512 shs. 34,544 are held by Sei Investments. Ls Invest Advisors Limited Liability, a Michigan-based fund reported 9,506 shs. 373,500 were reported by Gmt Cap. Renaissance Technologies Lc reported 0.05% of its capital in DaVita Inc. (NYSE:DVA).
DaVita Inc. (NYSE:DVA) Ratings Coverage
In total 7 analysts cover DaVita (NYSE:DVA). “Buy” rating has 3, “Sell” are 0, while 4 are “Hold”. 43% are bullish. 10 are the (NYSE:DVA)’s analyst reports since September 13, 2018 according to StockzIntelligence Inc. In Tuesday, February 19 report SunTrust maintained the stock with “Hold” rating. On Thursday, November 8 the rating was downgraded by Raymond James to “Market Perform”. The company rating was upgraded by Raymond James on Wednesday, November 28. On Thursday, November 8 the stock of DaVita Inc. (NYSE:DVA) earned “Sector Perform” rating by RBC Capital Markets. On Thursday, September 13 the firm has “Neutral” rating given by JP Morgan. On Tuesday, January 8 the firm has “Neutral” rating given by UBS. Listed here are DaVita Inc. (NYSE:DVA) PTs and latest ratings.
19/02/2019 Broker: SunTrust Rating: Hold New Target: $64 Maintain
14/02/2019 Broker: Barclays Capital Rating: Buy New Target: $68
08/01/2019 Broker: UBS Old Rating: Sell New Rating: Neutral Old Target: $64 New Target: $59 Upgrade
03/01/2019 Broker: Deutsche Bank Rating: Buy New Target: $60 Initiates Coverage On
14/12/2018 Broker: Barclays Capital Rating: Overweight New Target: $70 Initiates Coverage On
28/11/2018 Broker: Raymond James Old Rating: Market Perform New Rating: Outperform New Target: $70 Upgrade
16/11/2018 Broker: UBS Rating: Sell New Target: $64 Initiates Coverage On
08/11/2018 Broker: RBC Capital Markets Old Rating: Sector Perform New Rating: Sector Perform Old Target: $70 New Target: $78 Maintain
08/11/2018 Broker: Raymond James Old Rating: Strong Buy New Rating: Market Perform Downgrade
13/09/2018 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Upgrade
The stock decreased 0.55% or $0.32 during the last trading session, hitting $58.38.DaVita Inc. has volume of 365,956 shares. Since February 25, 2018 DVA has declined 13.60% and is downtrending. DVA underperformed by 13.60% the S&P 500.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease .The firm is valued at $9.71 billion. It operates through two divisions, DaVita Kidney Care and DaVita Medical Group.63.46 is the P/E ratio. The firm operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
Another two news for DaVita Inc. (NYSE:DVA) were recently brought out by: Nasdaq.com on February 15, 2019 with title “3 Big Stock Charts for Friday: Davita, Fastenal Company and BorgWarner – Nasdaq”. The other Seekingalpha.com‘s article was titled “DaVita HealthCare Partners Inc. (DVA) CEO Kent Thiry on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” and brought out on February 14, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.